Company acquired (location)

Acquired by or merged with (location)

Date reported

Date completed

Value (M)@

Terms/details

APRIL

Biofocus and Argenta service division operations of Galapagos NV (Mechelen, Belgium)

Charles River Laboratories International Inc. (Wilmington, Mass.)

3/14/14

4/2/14

$185

Galapagos sold its service division operations to Charles River for up to €134M (US$185M), including €129M in cash, and the company is eligible to receive a €5M earnout payment after 12 months, upon achievement of a revenue target for the divested service division

California Peptide Research Inc.

Echelon Biosciences Inc. (Salt Lake City)

4/17/14

4/17/14

ND

Echelon acquired California Peptide to offer its line of biochemicals and research peptides, and to further drive innovations in the peptide research and development markets

Cocrystal Discovery Inc. (Seattle)

Biozone Pharmaceuticals Inc. (Englewood Cliffs, N.J.)

1/3/14

4/18/14

ND

Companies finalized a planned merger with Biozone owning 40% and Cocrystal 60% of the combined company

Ipierian Inc. (San Francisco)

Bristol-Myers Squibb Co. (New York)

4/30/14

4/30/14

$175

BMS acquired Ipierian for $725M, including $175M in cash and milestone payments that could total $550M, plus royalties

Paloma Pharmaceuticals Inc. and Vasculomedics Inc. (Jamaica Plain, Mass.)

Restorgenex Corp. (Los Angeles)

4/2/14

4/2/14

ND

Restorgenex closed its acquisition of the two companies

Pernix Manufacturing LLC (Houston; unit of Pernix Therapeutics Holdings Inc.)

Woodfield Pharmaceutical LLC (Boca Raton, Fla.)

4/2/14

4/28/14

$1.2

Pernix divested its Houston-based manufacturing operations, to Woodfield, which acquired the entire operation and will assume the mortgage associated with the facility; Pernix will receive about $1.2M in net proceeds at closing and realize about $5M in annualized cost savings from the divestiture

Pharmacy Creations LLC (Randolph, N.J.)

Imprimis Pharmaceuticals Inc. (San Diego)

2/13/14

4/1/14

$0.6

Imprimis acquired Pharmacy Creations for $600,000 in cash, plus $50,000 and 215,900 shares if certain milestones are met

Shape Pharmaceuticals Inc. (Cambridge, Mass.)

Tetralogic Pharmaceuticals Corp. (Malvern, Pa.)

4/8/14

4/14/14

$13

Tetralogic acquired Shape for an up-front cash payment of $13M

MAY

California Stem Cell Inc. (Irvine, Calif.)

Neostem Inc. (New York)

4/15/14

5/18/14

$120

Neostem acquired California Stem Cell through a stock transaction, plus up to $90M in cash or Neostem shares as part of additional milestone and royalty payments; Neostem will issue up to about 5.33M shares of common stock, worth about $30M

Camp Nine Inc. (New York)

Relmada Therapeutics Inc.

5/20/14

5/20/14

$28

Relmada went public via a reverse merger with Camp Nine pursuant to a share exchange agreement, whereby Camp Nine acquired approximately 94% of the outstanding shares of Relmada

Euprotec Ltd. (Manchester, UK)

Evotec AG (Hamburg, Germany)

5/29/14

5/29/14

ND

Evotec acquired Euprotec in an all-stock transaction

Fabrus LLC (La Jolla, Calif.)

Senesco Technologies Inc. (Bridgewater, N.J.)

12/31/13

5/20/14

ND

Senesco completed its acquisition of Fabrus, issuing 6.9M shares of common stock, 160,202 options and about 3.6M warrants

Fibrotech Therapeutics Pty (Melbourne, Australia)

Shire plc (Dublin)

5/1/14

5/1/14

$75

Fibrotech was acquired by Shire for an up-front payment of $75M and undisclosed contingent payments based on the achievement of development and regulatory milestones

Inspiro Medical Ltd. (Israel)

Opko Health Inc. (Miami)

4/18/14

5/23/14

ND

Opko Health completed the acquisition of Inspiro

Lumena Pharmaceuticals Inc. (San Diego)

Shire plc (Dublin)

5/13/14

5/13/14

$260

Shire paid $260M up front, plus undisclosed milestones, for Lumena

Tenaxis Medical Inc. (Mountain View, Calif.)

The Medicines Co. (Parsippany, N.J.)

4/24/14

5/1/14

$58

The Medicines Co. acquired Tenaxis Medical Inc., paying $58M up front on closing and milestones of up to $112M contingent upon achieving certain commercial and, in pursuit of broader indications, regulatory approval milestones

JUNE

Andromeda Biotech Ltd. (Israel)

Hyperion Therapeutics Inc. (Brisbane, Calif.)

4/25/14

6/13/14

$20

Hyperion acquired Andromeda for $12.5M up front in cash, plus 312,869 shares of common stock, valued at $7.85M, for a total value of about $20M; the deal also includes potential regulatory and approval milestone payments totaling $120M, and up to $430M in commercial milestones, plus tiered contingent sales payments ranging from 10% on global net sales of up to $300M to 17% on net sales that exceed $1.2B

Cell therapy and regenerative medicine business of Sanofi SA (Paris)

Aastrom Biosciences Inc. (Ann Arbor, Mich.)

4/22/14

6/3/14

$6.5

Aastrom acquired the cell therapy and regenerative medicine (CTRM) business of Sanofi for $6.5M, with $4M payable in cash at closing and $2.5M payable in the form of a promissory note

Chelsea Therapeutics International Ltd. (Charlotte, N.C.)

H. Lundbeck A/S (Valby, Denmark)

5/9/14

6/24/14

$658

Lundbeck completed its acquisition of Chelsea for $6.44 per share in cash and nontransferable contingent value rights that may pay up to an additional $1.50 per share based on sales of Northera from 2015 through 2017; Chelsea is now a wholly owned subsidiary of Lundbeck

Combinatorx combination high-throughput screening business and related assets from Zalicus Inc. (Cambridge, Mass.)

Horizon Discovery Group plc (Cambridge, UK)

6/3/14

6/3/14

$8

Horizon completed the acquisition of the business and related assets from Zalicus for £4.74M (US$8M); the business will become Horizon Combinatorx Inc., a wholly owned subsidiary of Horizon

Egen Inc. (Huntsville, Ala.)

Celsion Corp. (Lawrenceville, N.J.)

6/11/14

6/23/14

$14

Celsion acquired Egen for cash and shares of Celsion totaling $14M, consisting of $10.6M up front in shares and $3.4M in cash; the deal also could include $30.4M in milestone payments

Genia Technologies Inc. (Mountain View, Calif.)

Roche AG (Basel, Switzerland)

6/3/14

6/3/14

$125

Roche paid $125M to acquire Genia; the purchase includes up to $225M in contingent payments based on milestone achievement

SKS Ocular LLC

Ohr Pharmaceutical Inc. (New York)

6/3/14

6/3/14

ND

Ohr closed an acquisition of the assets of SKS Ocular

Trillium Therapeutics Inc.

Stem Cell Therapeutics Corp. (Toronto)

6/3/14

6/3/14

ND

Stem Cell Therapeutics merged with its wholly owned subsidiary Trillium Therapeutics, which became the name of the combined company

JULY

Aesrx LLC (Newton, Mass.)

Baxter International Inc. (Deerfield, Ill.)

7/10/14

7/10/14

ND

Baxter acquired Aesrx, including rights to Aes-103 for treating the underlying mechanism of sickle cell disease, for an undisclosed initial payment and future payments based on specified development, regulatory and commercial milestones

Alergo Pharma Srl (Argentina)

Stallergenes SA (Antony, France)

7/22/14

7/22/14

ND

Stallergenes acquired the entire share capital of Alergo for an undisclosed amount

Assembly Pharmaceuticals Inc. (Indianapolis)

Ventrus Biosciences Inc. (New York)

5/20/14

7/11/14

ND

Assembly Biosciences Inc., of New York, began trading on Nasdaq under the ticker "ASMB" after going public through a reverse merger of Ventrus Biosciences and Assembly Pharmaceuticals

Cell Source (Israel) Ltd.

Cell Source Inc. (New York)

7/2/14

7/2/14

ND

Through a share exchange agreement, it acquired all of the outstanding shares of Cell Source (Israel) Ltd.

Cellectis AB (Paris)

Takara Bio Inc. (Otsu, Japan)

7/30/14

7/30/14

ND

Cellectis sold its subsidiary Cellectis AB to Takara Bio

Forest Laboratories Inc. (New York)

Actavis plc (Dublin)

2/19/14

7/2/14

$28B

Actavis completed the acquisition of Forest in a cash and equity transaction; in conjunction, the companies agreed to sell or relinquish their rights to four generic pharmaceuticals to settle Federal Trade Commission charges that the acquisition likely would be anticompetitive; under the proposed FTC settlement order, the companies agreed to relinquish their rights to market generic diltiazem hydrochloride to Valeant Pharmaceuticals International Inc.; to sell generic ursodiol and generic lamotrigine ODT to Impax Laboratories Inc.; and to sell generic propranolol hydrochloride to Catalent Pharma Solutions Inc.

Grupo Farmaceutico Somar (Mexico City)

Endo International plc (Dublin)

4/30/14

7/24/14

ND

Endo acquired Grupo for an undisclosed cash consideration

Labrys Biologics Inc. (San Mateo, Calif.)

Teva Pharmaceutical Industries Ltd. (Rehovot, Israel)

6/4/14

7/22/14

$825

Teva completed the acquisition of Labrys for $200M up front and up to $625M in pre-launch milestone payments

Precision Genome Engineering Inc. (Pregenen) (Seattle)

Bluebird Bio Inc. (Cambridge, Mass.)

7/2/14

7/2/14

$15.76

Bluebird issued former stakeholders of Pregenen 408,667 shares, worth about $15.76M, of Bluebird common stock, and paid or assumed about $4.9M of current liabilities; Pregenen and its stakeholders are eligible for a $15M preclinical milestone, a $20.1M clinical milestone, and up to $99.9M in commercial milestones

Topotarget A/S (Copenhagen)

Bioalliance Pharma SA (Paris)

4/17/14

7/25/14

ND

The companies merged with Topotarget shareholders receiving two new Bioalliance Pharma shares for every 27 shares they held, implying one-third ownership in the merged company by Topotarget investors; the new company will operate under the name Onxeo

Variation Biotechnologies (US) Inc. (Cambridge, Mass.)

Paulson Capital (Delaware) Corp.

7/29/14

7/29/14

ND

Variation merged with Paulson and will become a wholly owned subsidiary of Paulson, which will be known as VBI Vaccines Inc.

Zalicus Inc. (Cambridge, Mass.)

Epirus Pharmaceuticals Inc. (Boston)

4/17/14

7/15/14

ND

The combined company was renamed Epirus Biopharmaceuticals, focuses on the business of Epirus, operates under Epirus' management team, and its shares will trade on Nasdaq under the symbol EPRS